BLOG AND WHITEPAPERS
Recon takes an analytical look behind select developments in healthcare
Keep up with the Recon Strategy Insights
Get an email each time Recon takes an analytical look behind select developments in healthcare.
Search
- By Marc Herant
The opioid crisis and patient abandonment
A perspective from a February issue that I originally missed highlighting the plight of patients who have been on a long-term opioid regimen for chronic pain.…
- By Jacob Wiesenthal and Tory Wolff
There’s a major disruption looming in how the site-of-care for infusions is managed which will have repercussions for plan competition, delivery system economics, PE hunting for healthcare opportunity…
- By Marc Herant
Modern drug discovery is largely based on the identification and validation of a biochemical target, and then screening and optimizing molecules that engage that target. Over time, this has given rise…
- By Marc Herant
Gene therapy in beta-thalassemia and sickle cell anemia
Beta-thalassemia and sickle cell anemia are common genetic diseases of hemoglobin (Hb) which manifest themselves in the former through transfusi…
- By Marc Herant
In search of a diagnosis: deploying genomics at scale
A substantial number of children have a disease identified as “rare” without having any kind of causative diagnosis (autism is not a causative dia…
- By Sarah Dolman
New molecular diagnostics, especially tests based on next-generation sequencing and gene-panels, could revolutionize how diseases are evaluated. But experience shows that insurers won’t cover these te…